Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany

Figure 2

Monte Carlo simulation: acceptability curve for edoxaban 30 mg od (a), edoxaban 60 mg od (b), dabigatran 110 mg bid (c), dabigatran 150 mg bid (d), rivaroxaban 20 mg od (e), and apixaban 5 mg bid (f) compared to warfarin (results obtained from data of every NOAC study) with current market prices for a population starting with 65 years from a German health insurance perspective (reproduction of (c) to (f) with permission of the publisher of [5]).

(a)

(b)

(c)

(d)

(e)

(f)